UAE pioneers life-saving allergy treatment with first nasal adrenaline spray approval

The Emirates Drug Establishment has approved a groundbreaking nasal spray designed to treat severe allergic reactions, marking a regional first and a major step forward in emergency care.

The newly authorised medication, known as EURneffy, contains epinephrine and is available in 1 mg and 2 mg doses. It is approved for adults and children aged four years and above, with dosage determined based on body weight.

With this decision, the United Arab Emirates becomes the first country in the region to introduce an adrenaline nasal spray specifically designed to treat Anaphylaxis—a potentially life-threatening condition requiring immediate intervention.

Developed by ALK Abelló, the treatment offers a needle-free alternative to traditional injection-based epinephrine, addressing common challenges such as fear of needles and difficulty administering injections during emergencies.

Health officials highlighted that rapid delivery of epinephrine is critical in saving lives during severe allergic reactions. The nasal spray’s design allows for quick and simple use, even by untrained individuals, helping to reduce delays in treatment and improve patient outcomes.

The approval follows collaboration between the Emirates Drug Establishment and the manufacturer to accelerate access to the medication, reinforcing efforts to enhance healthcare readiness and patient safety across the UAE.

Officials said the move aligns with the country’s broader strategy to expand access to innovative treatments while maintaining high standards of safety and regulatory efficiency. The introduction of user-friendly emergency therapies is expected to strengthen response capabilities in critical situations and improve overall quality of care.

The development also underscores the UAE’s growing role as a hub for medical innovation, supported by a regulatory framework that enables rapid adoption of advanced pharmaceutical solutions aimed at improving public health and saving lives.